Galenica AG

Galenica AG

GALNF
Galenica AGUS flagOther OTC
115.00
USD
- -
- -
5.73BMarket Cap
Galenica AG
GALNF
(Other OTC)

Recent

price

115.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
56.53
58.3
60.69
64.13
64.45
67
70.4
77.36
72.15
75.15
78.67
82.97
Revenue per Share
- -
1.64
1.62
1.67
2.43
3
2.54
3.48
3.38
3.32
5.72
3.67
3.63
Basic EPS, GAAP
- -
0.85
1.77
2.44
1.85
2.57
4
3.41
5.51
3.36
3
3.86
4.9
Free Cash Flow per Basic Share
- -
1.08
0.92
0.92
- -
1.65
1.7
1.81
1.81
2.11
2.21
2.21
2.31
Dividend per Share
- -
4.61
5.08
6.59
0.1
0.1
20.69
21.59
25.06
25.2
29.76
31.32
30.03
Book Value per Share
- -
-7.66
-7.29
-6.18
3.44
3.37
3.11
2.77
4.3
3
7.96
8.75
1.43
Tangible Book Value per Share
- -
50
50
50
49
49
49
49
50
50
50
50
50
Basic Weighted Avg Shares
- -
2,826
2,915
3,035
3,141
3,165
3,301
3,480
3,835
3,588
3,746
3,921
4,136
Sales/Revenue/Turnover
- -
3.72
3.78
3.77
4.04
3.26
4.88
5.93
4.94
5.18
5.07
5.21
5.47
Operating Margin (%)
- -
41
41
42
40
41
91
96
98
100
103
110
116
Depreciation Expense
- -
82
81
83
119
148
125
172
168
165
285
183
181
Net Income, GAAP
- -
16.35
18.59
20.04
15.04
- -
23.31
17.2
17.16
17.02
15
14.4
17.31
Effective Tax Rate (%)
- -
2.9
2.78
2.75
3.78
4.66
3.79
4.95
4.37
4.6
7.62
4.67
4.38
Profit Margin (%)
143
156
192
250
330
339
269
265
299
97
261
300
137
Working Capital
764
764
764
765
382
- -
563
551
173
183
186
183
189
LT Debt
220
240
259
334
862
934
1,000
1,053
1,234
1,249
1,475
1,552
1,485
Total Equity
- -
7.64
7.69
6.96
7.91
- -
9.67
10.44
10.02
10.32
9.96
9.89
10.51
Return on Invested Capital (%)
- -
8.45
8.42
7.64
12.99
- -
15.68
10.65
10.9
11.4
18.21
10.96
10.78
Return on Capital (%)
- -
37.19
33.5
28.58
71.01
2,950.92
24.4
16.51
14.52
13.23
20.86
12.02
11.84
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.49%
7.47%
-4.31%
Free Cash Flow
16.12%
13.62%
26.86%
Net Income, GAAP
12.37%
6.35%
-1.01%
Sales/Revenue/Turnover
3.64%
3.66%
5.47%
Total Cash Common Dividend
- -
5.41%
4.48%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3,746
2024
- -
- -
- -
- -
3,921
2025
- -
- -
- -
- -
4,136

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5.72
2024
- -
- -
- -
- -
3.67
2025
- -
- -
- -
- -
3.63

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.21
2024
- -
- -
- -
- -
2.21
2025
- -
- -
- -
- -
2.31
Business
Galenica AG operates as a leading integrated healthcare service provider in Switzerland. The company conducts its activities through two primary segments, Products & Care and Logistics & IT; the Products & Care segment encompasses retail pharmacies under brands including Amavita, Sun Store and Coop Vitality, home care services via Bichsel HomeCare, online pharmacies such as Redcare Pharmacy through its stake and Mediservice, consumer health products marketed by Verfora including Perskindol, Triofan and brands from partners like Cooper Consumer Health, clinical nutrition and patient-specific blister packaging by Bichsel and Medifilm, digital platforms through Lifestage Solutions, mobile care home doctors via Emeda, and services for professionals such as complementary medicine via Spagyros; the Logistics & IT segment delivers pre-wholesale and wholesale distribution, storage, debt collection, master data systems, healthcare management solutions, group IT services and pharmaceutical information publications to pharmacies, drugstores, doctors, hospitals, care homes and suppliers. Galenica AG, founded in 1927 and headquartered in Bern, Switzerland, maintains nearly 380 bricks-and-mortar pharmacies, supports omni-channel distribution including online and at-home delivery, and serves both consumer and professional markets across Switzerland with a network of over 20 business units. In recent developments, Galenica completed the acquisition of Diagnostics Group GmbH, operating as Labor Team, on September 9, 2025, to launch Galenica Diagnostics and enter the medical laboratory sector as Switzerland's fourth-largest provider; the company increased its stake in Redcare Pharmacy to 10.3% in 2024, integrated it into Mediservice, and invested in Farmadomo Home Care Provider SA for a 33% share to expand clinical nutrition and blister packaging in southern Switzerland; additionally, Verfora assumed exclusive marketing and distribution of Cooper Consumer Health products including Duphalac, Legalon and Prosta-Urgenin from January 1, 2025, while Medifilm commissioned new blister packaging machines awaiting Swissmedic certification in early 2025 and a new quality management system rolled out across pharmacies in January 2025.

Company News

APIChat
  • Galenica AG (GALNF) Q4 2025 Earnings Call Transcript